Wallace M R, Moss R B, Beecham H J, Grace C J, Hersh E M, Peterson E, Murphy R, Shepp D H, Siegal F P, Turner J L, Safrin S, Carlo D J, Levine A M
U.S. Naval Medical Center-San Diego, California, USA.
J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 1;12(4):358-62. doi: 10.1097/00042560-199608010-00005.
In a clinical trial involving asymptomatic, HIV-seropositive subjects treated with either the HIV-1 immunogen (an inactivated, gp120-depleted HIV-1 virus in incomplete Freund's adjuvant) or an adjuvant control, we examined the relationship between changes in the percentage of CD4 cells over time and early clinical markers of HIV disease progression. Subjects who had an early clinical event were more likely to have a greater decline in the percentage of CD4 cells than those subjects who did not have a clinical event (p = 0.054). The greatest decline in CD4 percentage occurred within 10 weeks prior to a clinical event (mean 11% decrease from baseline). Subjects from the quartile with the greatest decline in CD4 percentage had a fivefold greater risk of having a clinical event than subjects from the quartile with the second largest decline (p = 0.045). These results demonstrate a relationship between changes in the percentage of CD4 cells and early clinical events. Further validation of this association may be useful in clinical monitoring and in evaluating therapies to treat HIV infection.
在一项针对无症状、HIV血清反应阳性受试者的临床试验中，这些受试者接受了HIV-1免疫原（一种在不完全弗氏佐剂中的灭活、gp120缺失的HIV-1病毒）或佐剂对照治疗，我们研究了CD4细胞百分比随时间的变化与HIV疾病进展的早期临床标志物之间的关系。发生早期临床事件的受试者比未发生临床事件的受试者更有可能出现CD4细胞百分比的更大幅度下降（p = 0.054）。CD4百分比的最大降幅发生在临床事件前10周内（平均较基线下降11%）。CD4百分比降幅最大的四分位数中的受试者发生临床事件的风险是降幅第二大的四分位数中的受试者的五倍（p = 0.045）。这些结果证明了CD4细胞百分比的变化与早期临床事件之间的关系。这种关联的进一步验证可能有助于临床监测和评估治疗HIV感染的疗法。
